PT-141

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin-4 receptor agonist that acts centrally in the hypothalamus to increase sexual desire. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptorreceptor agonist and the first FDA-approved pharmacotherapy to target the central nervous system for sexual dysfunction. Approved in June 2019 under the brand name Vyleesi, it is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women — a condition characterized by low sexual desire causing marked distress that affects an estimated 10% of adult women in the United States. Unlike sildenafil, tadalafil, and other phosphodiesterase-5 inhibitors that act peripherally on vascular smooth muscle, PT-141 works upstream in the brain, modulating the neural circuits that govern motivation and desire rather than simply facilitating blood flow.

PT-141 was discovered serendipitously during research on Melanotan II (MT-II), a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) originally developed as a sunless tanning agent. Researchers at the University of Arizona noted that MT-II produced spontaneous erections in male volunteers — an unexpected melanocortin effect. Subsequent medicinal chemistry work produced bremelanotide, a cyclic variant engineered to eliminate the prominent blood-pressure liability of MT-II while retaining its CNS-mediated pro-sexual activity. The cyclic structure confers resistance to peptidase degradation and enables subcutaneous delivery with roughly 100% bioavailability.

Clinically, PT-141 is administered as a 1.75 mg subcutaneous auto-injector approximately 45 minutes before anticipated sexual activity. Onset of desire-enhancing effects typically occurs within 30–60 minutes and lasts 6–12 hours, with a plasma half-life of approximately 2.7 hours. The RECONNECT Phase 3 trials demonstrated statistically significant but small improvements in sexual desire and reductions in desire-related distress in premenopausal women with HSDD. In men, early-phase trials showed statistically significant erectile responses in those who do not respond adequately to PDE5 inhibitors, which drove off-label use.

Beyond sexual function, melanocortin system engagement by PT-141 influences appetite, mood, and inflammation, reflecting the broad biological role of MC4R in energy homeostasis and autonomic regulation. The most common adverse effect is nausea, reported by about 40% of women in the long-term extension study and attributed to MC4R activation in the dorsal motor nucleus of the vagus nerve. A transient increase in blood pressure is also observed, and the FDA label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease.

PT-141 exerts its pro-sexual effects primarily by activating melanocortin-4 receptors (MC4R) in key hypothalamic nuclei, including the medial preoptic area (mPOA), the paraventricular nucleus (PVN), and the arcuate nucleus. MC4R is a Gs-coupled receptor; its activation elevates intracellular cAMP, which in the mPOA triggers downstream release of dopamine into the mesolimbic and nigrostriatal pathways. This dopaminergic surge is directly responsible for the motivational and desire-amplifying effects of PT-141 — paralleling how endogenous α-MSH participates in arousal states. This mechanism is entirely distinct from PDE5 inhibitors like sildenafil, which amplify nitric oxide–cGMP signaling in penile smooth muscle without engaging motivational circuitry.

MC4R knockout mouse studies have confirmed that MC4R is necessary for both the erectile and libido-enhancing effects of bremelanotide: animals lacking MC4R show no response to PT-141, establishing that this receptor is the functional target rather than an epiphenomenon. PT-141 also binds MC3R with lower affinity; MC3R modulation may contribute to anti-inflammatory signaling and to the complex appetite-suppression effects occasionally reported by users. The peptide does not meaningfully activate MC1R (tanning/pigmentation) or MC2R (ACTH/cortisol), which is why melanogenesis is far less pronounced with PT-141 than with its precursor Melanotan II.

Pharmacokintetically, PT-141 reaches peak plasma concentration (Cmax) approximately 1 hour after subcutaneous injection and has a terminal half-life of ~2.7 hours. It crosses the blood-brain barrier to achieve hypothalamic concentrations sufficient for receptor activation within 30–45 minutes post-injection. Nausea — the most prominent adverse effect — arises from MC4R activation in the dorsal motor nucleus of the vagus nerve, which controls gastric motility; this central vagal mechanism explains why antiemetics that act peripherally are less effective than those with CNS activity. The transient blood-pressure elevation observed in clinical trials is attributed to MC4R-mediated sympathetic activation; see the current Vyleesi prescribing information for its magnitude and time course.

The pivotal human evidence for PT-141 comes from the RECONNECT program — two identical, randomized, double-blind, placebo-controlled Phase 3 trials in 1,267 premenopausal women with HSDD (Kingsberg et al., Obstet Gynecol, 2019). The co-primary endpoints were change from baseline to end of study in the Female Sexual Function Index desire domain score and in Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) item 13. PT-141 1.75 mg significantly outperformed placebo on both endpoints in both trials, but the absolute effects were small: desire improved by 0.30 points in study 301 and 0.42 in study 302 (integrated 0.35), and distress fell by 0.37 and 0.29 points respectively (integrated 0.33). Number of satisfying sexual events was not a co-primary endpoint, and the publication does not report a significant increase in it. Nausea, flushing and headache each occurred in 10% or more of bremelanotide recipients and more often than on placebo. In the 52-week open-label extension (Simon et al., 2019), 684 of the 856 eligible women enrolled and 272 completed; treatment-related nausea was reported by 40.4%, flushing 20.6% and headache 12.0%, with no new safety signals and sustained symptom improvement.

In men, the key Phase 2 data come from Rosen et al. (Int J Impot Res, 2004), a proof-of-concept study of subcutaneously administered PT-141. In healthy male subjects, doses from 0.3 to 10 mg produced a statistically significant erectile response by RigiScan above 1.0 mg. Men with erectile dysfunction who reported an inadequate response to sildenafil 100 mg received placebo, 4 mg, or 6 mg PT-141 in a crossover design with visual sexual stimulation, and the erectile response was statistically significant at both doses. The publication does not report responder percentages, so no response-rate figures are cited here. This finding positioned PT-141 as a potential second-line option for PDE5 inhibitor non-responders and drove off-label use in men despite no FDA approval for this indication.

Dose-finding for the approved women's dose came from a Phase 2b dose-ranging trial in premenopausal women with HSDD and mixed HSDD/female sexual arousal disorder. In the published responder analysis of that trial (Althof et al., J Sex Med, 2019), all seven patient-reported outcome endpoints reached statistical significance versus placebo at the 1.75 mg dose in the overall modified intention-to-treat population, and the responder definitions derived there were carried into the Phase 3 RECONNECT program.

An earlier study in women (Diamond et al., J Sex Med, 2006) tested a single 20 mg intranasal dose in 18 premenopausal women with female sexual arousal disorder. More women reported moderate or high sexual desire after bremelanotide than placebo, but vaginal vasocongestion measured by photoplethysmography did not change significantly — a useful reminder that the peptide's signal is on subjective desire rather than genital blood flow.

The overall body of evidence supports PT-141 as a mechanistically novel treatment with a consistent but small clinical signal in women with HSDD, plus early-phase support in men who fail PDE5 inhibition. The main limitations for broader adoption are the nausea burden and the blood pressure contraindication.[1][2][3][4][5]

Peptides commonly paired with PT-141 for synergistic effects.